Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

PHASE2CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

March 22, 2019

Conditions
Contraception
Interventions
DRUG

VeraCept

IUD placement of VeraCept

Trial Locations (12)

Unknown

Essential Access Health (formerly California Family Health Council), Burbank

Essential Access Health (formerly California Family Health Council), Los Angeles

University of California Davis Health System, Sacramento

University of Colorado, Aurora

Healthcare Clinical Data, Inc, Miami

Columbia University Medical Center, New York

University of Cincinnati, Cincinnati

Oregon Health and Sciences University, Portland

Clinical Research of Philadelphia, Philadelphia

University of Pennsylvania, Philadelphia

Advanced Research Associates, Corpus Christi

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Premier Research

OTHER

lead

Sebela Women's Health Inc.

INDUSTRY